We are thrilled to announce the successful completion of the IND-HOME trial, an Irish randomized clinical trial comparing the use of DILAPAN-S and dinoprostone vaginal insert in an outpatient setting for nulliparous women who had agreed to elective induction of labor (IOL) at 39 weeks.

The study was recently spotlighted at the Society for Maternal-Fetal Medicine’s (SMFM) 2024 Annual Pregnancy Meeting, where the first set of data was presented, marking a promising advancement in the field of obstetrics.

„Both DILAPAN-S and PROPESS, when used for 24-hour insertions, achieved comparably high vaginal delivery rates, with 75% of participants successfuly delivering vaginaly, and with no significant adverse maternal or neonatal outcomes.“

• • • • • • • Sarah M. Nicholson, lead author

This outcome highlights the potential of outpatient induction of labor (IOL) as a viable and effective option for managing the growing preference among nulliparous patients for 39-week inductions.

The IND-HOME trial’s findings are particularly noteworthy for their potential to transform IOL practices. By enabling patients to undergo a significant portion of the cervical ripening process at home, with minimal returns before the scheduled admission time, cervical ripening agents such as DILAPAN-S can significantly alleviate the resource demands on labor wards, offering a more patient-centered approach to childbirth. This study empowers obstetricians to confidently adopt outpatient IOL, providing a highly effective solution that aligns with the evolving needs and preferences of expectant mothers.

Stay tuned for more updates and detailed findings from the IND-HOME trial.